1
|
Alhawari H, Obeidat Z, Wahbeh L, Mismar A, Younis N, Jafar H, Momani M, Alsabatin N, Awidi A, Alhawari H. Discovering a novel genetic variant in 11 family members who had isolated pheochromocytoma linked to von Hippel-Lindau (VHL) syndrome, aligning with the type 2c phenotype. Blood Press 2024; 33:2355268. [PMID: 38824681 DOI: 10.1080/08037051.2024.2355268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Accepted: 05/06/2024] [Indexed: 06/04/2024]
Abstract
INTRODUCTION Von Hippel-Lindau disease (e.g. VHL) is an autosomal dominant multi-organ cancer syndrome caused by a mutation in the VHL tumour suppressor gene. In this study, we introduce a novel genetic variant found in 11 family members diagnosed initially with isolated Pheochromocytoma. Subsequent findings revealed its association with VHL syndrome and corresponds to the Type 2 C phenotype. METHODS The VHL gene was amplified through the utilisation of the polymerase chain reaction (PCR). PCR fragments were sequenced using bidirectional Sanger sequencing, using BigDye™ Terminator v3.1 Cycle Sequencing Kit, running on the 3500 genetic analyser. Results were assembled and analysed Using Software SeqA and chromas pro. RESULTS A heterozygous in-frame duplication of three nucleotides, specifically ATG, c.377_379dup; p.Asp126dup in exon 2, was identified in all the patients tested within the pedigree. CONCLUSION In this study, we disclose the identification of a novel genetic variant in a Jordanian family, affecting eleven family members with pheochromocytoma associated with VHL disease. This finding underscores the importance of screening family members and contemplating genetic testing for individuals newly diagnosed with pheochromocytoma and could enhance our comprehension of the potential adverse consequences associated with VHL germline mutations.
Collapse
Affiliation(s)
- Hussein Alhawari
- Department of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan
| | - Zaina Obeidat
- Department of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan
| | - Lina Wahbeh
- Department of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan
| | - Ayman Mismar
- Department of Special Surgery, School of Medicine, The University of Jordan, Amman, Jordan
| | - Nedal Younis
- Department of Special Surgery, School of Medicine, The University of Jordan, Amman, Jordan
| | - Hanan Jafar
- Department of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan
| | - Munther Momani
- Department of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan
| | - Nedal Alsabatin
- Department of Special Surgery, School of Medicine, The University of Jordan, Amman, Jordan
| | - Abdalla Awidi
- Department of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan
| | - Hussam Alhawari
- Department of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan
| |
Collapse
|
2
|
Szegedi K, Szabó Z, Kállai J, Király J, Szabó E, Bereczky Z, Juhász É, Dezső B, Szász C, Zsebik B, Flaskó T, Halmos G. Potential Role of VHL, PTEN, and BAP1 Mutations in Renal Tumors. J Clin Med 2023; 12:4538. [PMID: 37445575 DOI: 10.3390/jcm12134538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 07/04/2023] [Accepted: 07/05/2023] [Indexed: 07/15/2023] Open
Abstract
The genetic profiling of renal tumors has revealed genomic regions commonly affected by structural changes and a general genetic heterogeneity. The VHL, PTEN, and BAP1 genes are often mutated in renal tumors. The frequency and clinical relevance of these mutations in renal tumors are still being researched. In our study, we investigated VHL, PTEN, and BAP1 genes and the sequencing of 24 samples of patients with renal tumors, revealing that VHL was mutated at a noticeable frequency (25%). Six of the investigated samples showed mutations, and one genetic polymorphism (rs779805) was detected in both heterozygote and homozygote forms. PTEN gene mutation was observed in only one sample, and one specimen showed genetic polymorphism. In the case of the BAP1 gene, all of the samples were wild types. Interestingly, VHL mutation was detected in two female patients diagnosed with AML and in one with oncocytoma. We assume that VHL or PTEN mutations may contribute to the development of human renal cancer. However, the overall mutation rate was low in all specimens investigated, and the development and prognosis of the disease were not exclusively associated with these types of genetic alterations.
Collapse
Affiliation(s)
- Krisztián Szegedi
- Department of Urology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
- Doctoral School of Pharmaceutical Sciences, University of Debrecen, 4032 Debrecen, Hungary
| | - Zsuzsanna Szabó
- Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary
| | - Judit Kállai
- Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
| | - József Király
- Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary
| | - Erzsébet Szabó
- Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary
| | - Zsuzsanna Bereczky
- Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
| | - Éva Juhász
- Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
| | - Balázs Dezső
- Department of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
- Department of Oral Pathology and Microbiology, Faculty of Dentistry, University of Debrecen, 4032 Debrecen, Hungary
| | - Csaba Szász
- Department of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
| | - Barbara Zsebik
- Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary
| | - Tibor Flaskó
- Department of Urology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
| | - Gábor Halmos
- Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary
| |
Collapse
|
3
|
Chen Y, Chen J, Jiang Y, Lin X. Clinicopathological analysis of extraneural sporadic haemangioblastoma occurring in the tongue. BMJ Case Rep 2023; 16:16/5/e255581. [PMID: 37258051 DOI: 10.1136/bcr-2023-255581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023] Open
Abstract
Haemangioblastoma is a morphologically distinctive tumour with uncertain histogenesis, typically occurring in the cerebellum, brain stem or spinal cord and less commonly in extraneural locations. Here, we present a case of haemangioblastoma occurring in the tongue, which is the first reported case in terms of the pathogenic site. The tumour was morphologically indistinguishable from central nervous system haemangioblastoma, that is, neoplastic stromal cells with cytoplasmic vacuolisation and abundant small vessels. Immunohistochemical studies revealed that the tumour cells were positive for S100, NSE, CD56, Syn, EMA, vimentin and α-inhibin, while negative for CK, SMA, factor Ⅷ, D2-40 and GFAP. Immunostainings for CD34 and CD31 outlined the rich and delicate vascular channels. Ki-67 expression was presented in approximately 3% of tumour cells. Primary haemangioblastoma has not been previously described at this site, and this case emphasises the need to consider haemangioblastoma in the differential diagnoses of neoplasms occurring in the tongue.
Collapse
Affiliation(s)
- Yacun Chen
- School of Chinese Medicine, The University of Hong Kong, Hong Kong, China
| | - Jie Chen
- School of Chinese Medicine, The University of Hong Kong, Hong Kong, China
- Department of Orthopedics, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Ye Jiang
- Department of Pathology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
| | - Xiang Lin
- School of Chinese Medicine, The University of Hong Kong, Hong Kong, China
- Department of Chinese Medicine, the University of Hong Kong-Shenzhen Hospital (HKU-SZH), Shenzhen, China
| |
Collapse
|
4
|
Leinøe E, Brøns N, Rasmussen AØ, Gabrielaite M, Zaninetti C, Palankar R, Zetterberg E, Rosthøj S, Ostrowski SR, Rossing M. The Copenhagen founder variant GP1BA c.58T>G is the most frequent cause of inherited thrombocytopenia in Denmark. J Thromb Haemost 2021; 19:2884-2892. [PMID: 34333846 PMCID: PMC9292710 DOI: 10.1111/jth.15479] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 07/20/2021] [Accepted: 07/29/2021] [Indexed: 12/17/2022]
Abstract
BACKGROUND The classic Bernard-Soulier syndrome (BSS) is a rare inherited thrombocytopenia (IT) associated with severe thrombocytopenia, giant platelets, and bleeding tendency caused by homozygous or compound heterozygous variants in GP1BA, GP1BB, or GP9. Monoallelic BSS (mBSS) associated with mild asymptomatic macrothrombocytopenia caused by heterozygous variants in GP1BA or GP1BB may be a frequent cause of mild IT. OBJECTIVE We aimed to examine the frequency of mBSS in a consecutive cohort of patients with IT and to characterize the geno- and phenotype of mBSS probands and their family members. Additionally, we set out to examine if thrombopoietin (TPO) levels differ in mBSS patients. PATIENTS/METHODS We screened 106 patients suspected of IT using whole exome- or whole genome sequencing and performed co-segregation analyses of mBSS families. All probands and family members were phenotypically characterized. Founder mutation analysis was carried out by certifying that the probands were unrelated and the region around the variant was shared by all patients. TPO was measured by solid phase sandwich ELISA. RESULTS We diagnosed 14 patients (13%) with mBSS associated with heterozygous variants in GP1BA and GP1BB. Six unrelated probands carried a heterozygous variant in GP1BA (c.58T>G, p.Cys20Gly) and shared a 2.0 Mb region on chromosome 17, confirming that it is a founder variant. No discrepancy of TPO levels between mBSS patients and wild-type family members (P > .05) were identified. CONCLUSION We conclude that the most frequent form of IT in Denmark is mBSS caused by the Copenhagen founder variant.
Collapse
Affiliation(s)
- Eva Leinøe
- Department of HematologyCopenhagen University HospitalRigshospitaletCopenhagenDenmark
- Center for Genomic MedicineCopenhagen University HospitalRigshospitaletCopenhagenDenmark
| | - Nanna Brøns
- Department of HematologyCopenhagen University HospitalRigshospitaletCopenhagenDenmark
| | | | - Migle Gabrielaite
- Center for Genomic MedicineCopenhagen University HospitalRigshospitaletCopenhagenDenmark
| | - Carlo Zaninetti
- Department of Immunology and Transfusion MedicineUniversity Medicine GreifswaldGreifswaldGermany
| | - Raghavendra Palankar
- Department of Immunology and Transfusion MedicineUniversity Medicine GreifswaldGreifswaldGermany
| | | | - Steen Rosthøj
- Department of PediatricsAalborg University HospitalAalborgDenmark
| | - Sisse Rye Ostrowski
- Department of Clinical ImmunologyCopenhagen University HospitalRigshospitaletCopenhagenDenmark
| | - Maria Rossing
- Center for Genomic MedicineCopenhagen University HospitalRigshospitaletCopenhagenDenmark
| |
Collapse
|
5
|
Salama Y, Albanyan S, Szybowska M, Bullivant G, Gallinger B, Giles RH, Asa S, Badduke C, Chiorean A, Druker H, Ezzat S, Hannah‐Shmouni F, Hernandez KG, Inglese C, Jani P, Kaur Y, Krema H, Krimus L, Laperriere N, Lichner Z, Mete O, Sit M, Zadeh G, Jewett MA, Malkin D, Stockley T, Wasserman JD, Xu W, Schachter NF, Kim RH. Comprehensive characterization of a Canadian cohort of von Hippel‐Lindau disease patients. Clin Genet 2019; 96:461-467. [DOI: 10.1111/cge.13613] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 07/06/2019] [Accepted: 07/18/2019] [Indexed: 12/14/2022]
Affiliation(s)
- Yasser Salama
- Faculty of MedicineUniversity of Toronto Toronto Ontario Canada
| | - Saleh Albanyan
- Clinical and Metabolic GeneticsHospital for Sick Children Toronto Ontario Canada
| | - Marta Szybowska
- Fred A Litwin Family Centre in Genetic MedicineUniversity Health Network Toronto Ontario Canada
| | - Garrett Bullivant
- Department of Molecular GeneticsUniversity of Toronto Toronto Ontario Canada
| | - Bailey Gallinger
- Clinical and Metabolic GeneticsHospital for Sick Children Toronto Ontario Canada
| | - Rachel H. Giles
- Department of Nephrology and HypertensionUniversity Medical Center Utrecht Utrecht The Netherlands
| | - Sylvia Asa
- Department of Laboratory Medicine and PathobiologyUniversity Health Network Toronto Ontario Canada
| | - Chansonette Badduke
- Advanced Molecular Diagnostics LaboratoryPrincess Margaret Hospital Cancer Centre Toronto Ontario Canada
| | - Andreea Chiorean
- Clinical and Metabolic GeneticsHospital for Sick Children Toronto Ontario Canada
| | - Harriet Druker
- Department of Molecular GeneticsUniversity of Toronto Toronto Ontario Canada
| | - Shereen Ezzat
- Department of MedicineUniversity Health Network Toronto Ontario Canada
| | - Fady Hannah‐Shmouni
- Section 6 on Endocrinology and GeneticsNational Institutes of Health Bethesda Mary Land
| | | | - Cara Inglese
- Clinical and Metabolic GeneticsHospital for Sick Children Toronto Ontario Canada
| | - Payal Jani
- McMaster University Hamilton Ontario Canada
| | - Yuvreet Kaur
- Faculty of MedicineUniversity of Toronto Toronto Ontario Canada
| | - Hatem Krema
- Department of Ophthalmology and Vision SciencesUniversity Health Network, University of Toronto Toronto Ontario Canada
| | - Lior Krimus
- Faculty of MedicineUniversity of Toronto Toronto Ontario Canada
| | - Normand Laperriere
- Department of Radiation OncologyUniversity of Toronto Toronto Ontario Canada
| | - Zsuzanna Lichner
- Sinai Health SystemLunenfeld‐Tanenbaum Research Institute Toronto Ontario Canada
| | - Ozgur Mete
- Department of Laboratory Medicine and PathobiologyUniversity Health Network Toronto Ontario Canada
| | - Marisa Sit
- Department of Ophthalmology and Vision SciencesUniversity Health Network, University of Toronto Toronto Ontario Canada
| | - Gelareh Zadeh
- Division of NeurosurgeryToronto Western Hospital Toronto Ontario Canada
| | - Michael A.S. Jewett
- Department of SurgeryUniversity Health Network, University of Toronto Toronto Ontario Canada
| | - David Malkin
- Department of PaediaticsHospital for Sick Children Toronto Ontario Canada
| | - Tracy Stockley
- Department of Laboratory Medicine and PathobiologyUniversity Health Network Toronto Ontario Canada
| | | | - Wei Xu
- Department of BiostatisticsPrincess Margaret Hospital Cancer Centre Toronto Ontario Canada
| | | | - Raymond H. Kim
- Clinical and Metabolic GeneticsHospital for Sick Children Toronto Ontario Canada
- Fred A Litwin Family Centre in Genetic MedicineUniversity Health Network Toronto Ontario Canada
- Department of MedicineUniversity Health Network Toronto Ontario Canada
| |
Collapse
|
6
|
Guo X, Gao L, Hong X, Guo D, Di W, Wang X, Xu Z, Xing B. Whole-exome sequencing and immunohistochemistry findings in von Hippel-Lindau disease. Mol Genet Genomic Med 2019; 7:e880. [PMID: 31317677 PMCID: PMC6732316 DOI: 10.1002/mgg3.880] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 05/07/2019] [Accepted: 07/08/2019] [Indexed: 12/21/2022] Open
Abstract
Background von Hippel–Lindau (VHL) disease has a hereditary, autosomal dominant pattern, and multiple tumors can develop in multiple organs of a single patient. However, the exact mechanisms of tumorigenesis are unclear, and further studies are needed to clarify whether the same signaling pathways are involved in different VHL‐related tumors. Methods Whole‐exome sequencing (WES) of tumor and paired peripheral blood samples were performed for a VHL disease pedigree. A bioinformatics analysis was conducted to identify candidate somatic single‐nucleotide variants (SNVs) present in all tumor tissues. Sanger sequencing was then used to validate the SNVs identified using WES. Immunohistochemistry was performed to analyze components of the mTOR pathway, which was abnormally activated in tumor tissues. Results Two hemangioblastomas and two renal cell carcinomas were sequenced. The bioinformatics analysis revealed a VHL somatic variant in all tumors; no other SNV was detected. Immunohistochemistry showed the abnormal expression of the phospho‐S6 ribosomal protein in the hemangioblastomas, but not in the renal clear cell carcinomas. Conclusion Except for a SNV in the VHL gene, no other somatic SNVs were detected using WES. The phospho‐S6 ribosomal protein in the mTOR pathway is a potential target in VHL‐related cerebellum hemangioblastomas.
Collapse
Affiliation(s)
- Xiaopeng Guo
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
| | - Lu Gao
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
| | - Xiafei Hong
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
| | - Dan Guo
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Corelabs, Beijing, P.R. China.,Clinical Bio-bank, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
| | - Wenyu Di
- Department of Pathology, Xinxiang Medical University First Affiliated Hospital, Weihui, P.R. China
| | - Xiaoman Wang
- State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
| | - Zhiqin Xu
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
| | - Bing Xing
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
| |
Collapse
|
7
|
Binderup MLM, Stendell AS, Galanakis M, Møller HU, Kiilgaard JF, Bisgaard ML. Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease. Br J Ophthalmol 2017; 102:942-947. [DOI: 10.1136/bjophthalmol-2017-310884] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 08/15/2017] [Accepted: 09/09/2017] [Indexed: 12/15/2022]
Abstract
Background and aimsWe aimed to determine the frequency of von Hippel-Lindau disease (vHL) as the underlying cause of retinal hemangioblastoma and to estimate retinal hemangioblastoma incidence and prevalence in a national cohort study.MethodsThrough the national patient register and vHL research database, we identified 81 patients diagnosed with a retinal hemangioblastoma in Denmark between 1977 and 2014. Consent was obtained for 54 living and 10 deceased patients with retinal hemangioblastoma. For each participant, we collected medical records and family information. Almost all (63 of 64) participants were or had previously been tested for mutations in the VHL gene.ResultsOverall, 84% of the participants (54 of the 64) had vHL. Compared with the non-vHL patients, the vHL patients had their first retinal hemangioblastoma at a younger age (22.5 vs 40 years), and were more likely to have an asymptomatic first hemangioblastoma (80% vs 20%). Overall, 76% (41 of 54) of the vHL patients had a family history of vHL, while none of the patients without vHL did. Despite the rarity of the disease, on average more than eight new tumours are diagnosed each year due to multiple tumour development in vHL patients. The estimated prevalence of patients with retinal hemangioblastoma was up to 1 in 73 080 individuals.ConclusionIn the first national study in which almost all participants were genetically tested, vHL was the underlying cause of retinal hemangioblastoma in 84% of cases; more often than previously reported. We recommend that genetic and clinical vHL screening should be performed in all patients with retinal hemangioblastoma.
Collapse
|
8
|
Binderup MLM, Galanakis M, Budtz-Jørgensen E, Kosteljanetz M, Luise Bisgaard M. Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark. Eur J Hum Genet 2016; 25:301-307. [PMID: 27966541 DOI: 10.1038/ejhg.2016.173] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 10/12/2016] [Accepted: 11/15/2016] [Indexed: 11/09/2022] Open
Abstract
Von Hippel-Lindau disease (vHL) is a rare hereditary tumour predisposition with multiorgan involvement that is not always easily recognized. The disease is reported to be almost fully penetrant at age 60 years. Previous estimates of vHL prevalence and incidence are all regional and vary widely. Most are >20 years old and prone to selection bias because of inclusion of only clinically affected vHL patients who were diagnosed before genetic testing was available. In an unselected cohort of all known Danish carriers of a disease-causing VHL variant, we assessed vHL penetrance on a national basis. We further used national health registers to identify individuals who fulfilled the clinical diagnostic vHL criteria based on their registered diagnostic codes, but had not been diagnosed with vHL. We also assessed the medical histories of first-degree relatives to identify familial cases. This study gives the first national estimates of vHL prevalence (1 in 46 900 individuals) and birth incidence (1 in 27 300 live births). vHL has been underdiagnosed in Denmark, and as many as 25% of the overall vHL cohort (diagnosed+undiagnosed patients) have a missed diagnosis in spite of fulfilling the international diagnostic criteria. We found an overall penetrance of 87% at age 60 years. When considering only vHL patients who have not attended surveillance, 20% will still be asymptomatic at age 60 years. This should be considered in the context of genetic counselling, especially when assessing the risk of vHL in asymptomatic adult first-degree relatives who are often not genetically tested.
Collapse
Affiliation(s)
| | - Michael Galanakis
- Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Esben Budtz-Jørgensen
- Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.,Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark
| | | | - Marie Luise Bisgaard
- Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
9
|
Genetic screening of the FLCN gene identify six novel variants and a Danish founder mutation. J Hum Genet 2016; 62:151-157. [PMID: 27734835 DOI: 10.1038/jhg.2016.118] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Revised: 08/12/2016] [Accepted: 09/06/2016] [Indexed: 12/19/2022]
Abstract
Pathogenic germline mutations in the folliculin (FLCN) tumor suppressor gene predispose to Birt-Hogg-Dubé (BHD) syndrome, a rare disease characterized by the development of cutaneous hamartomas (fibrofolliculomas), multiple lung cysts, spontaneous pneumothoraces and renal cell cancer. In this study, we report the identification of 13 variants and three polymorphisms in the FLCN gene in 143 Danish patients or families with suspected BHD syndrome. Functional mini-gene splicing analysis revealed that two intronic variants (c.1062+2T>G and c.1177-5_1177-3del) introduced splicing aberrations. Eleven families exhibited the c.1062+2T>G mutation. Combined single nucleotide polymorphism array-haplotype analysis showed that these families share a 3-Mb genomic fragment containing the FLCN gene, revealing that the c.1062+2T>G mutation is a Danish founder mutation. On the basis of in silico prediction and functional splicing assays, we classify the 16 identified variants in the FLCN gene as follows: nine as pathogenic, one as likely pathogenic, three as likely benign and three as polymorphisms. In conclusion, the study describes the FLCN mutation spectrum in Danish BHD patients, and contributes to a better understanding of BHD syndrome and management of BHD patients.
Collapse
|
10
|
Binderup MLM, Jensen AM, Budtz-Jørgensen E, Bisgaard ML. Survival and causes of death in patients with von Hippel-Lindau disease. J Med Genet 2016; 54:11-18. [PMID: 27539272 DOI: 10.1136/jmedgenet-2016-104058] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Revised: 07/22/2016] [Accepted: 07/27/2016] [Indexed: 11/03/2022]
Abstract
BACKGROUND Historically, the survival of patients with von Hippel-Lindau disease (vHL) has been poorer than that of the general population. We aimed to determine whether the survival of VHL mutation carriers and their risk of vHL-related death has changed over time and how it has been affected by sex, genotype and surveillance attendance. METHODS In a retrospective cohort study, we included all known Danish vHL families with a VHL mutation. We assessed the survival and causes of death for 143 VHL mutation carriers using Cox regression models and compared vHL survival with that of 137 siblings without vHL. vHL life expectancy was compared with the general population using a relative survival model. RESULTS The estimated mean life expectancies for male and female patients born in 2000 were 67 and 60 years, respectively. Survival is influenced by the sex and genotype of the patient. Female patients have a significantly higher risk of vHL-related death than male patients (HR=2.25, 95% CI 1.20 to 4.20, p=0.011). Overall, 79% (53 of 67) of deaths were vHL-related, but the risk of vHL-related death has decreased over time, as has the frequency of renal cell carcinoma (RCC)-related death. Surveillance is especially beneficial for truncating mutation carriers, who have the greatest RCC and central nervous system (CNS) hemangioblastoma risk. CONCLUSIONS vHL survival has improved over time and has become closer to that of siblings without vHL and the general population. Even though the risk of vHL-related death has decreased significantly, the main cause of death is still CNS hemangioblastomas and hence improved treatment options are essential.
Collapse
Affiliation(s)
| | - Annette Møller Jensen
- Department of Clinic of Cognitive Therapy, Mental Health Center Sct. Hans, Capital Region of Denmark, Roskilde, Denmark
| | - Esben Budtz-Jørgensen
- Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.,Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark
| | - Marie Luise Bisgaard
- Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
11
|
Yuan P, Sun Q, Liang H, Wang W, Li L, Wang Y, Deng H, Lai L, Chen X, Zhou X. Germline mutations in the VHL gene associated with 3 different renal lesions in a Chinese von Hippel-Lindau disease family. Cancer Biol Ther 2016; 17:599-603. [PMID: 27057652 DOI: 10.1080/15384047.2016.1167293] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
Von Hippel-Lindau (VHL) disease is a rare autosomal dominant inherited cancer syndrome that is characterized by hemangioblastomas in the central nervous system and retina, renal cell carcinoma and cysts, pancreatic tumors and cysts, and pheochromocytoma. The underlying gene in this disease is the VHL tumor suppressor gene. We characterized a family with 2 affected siblings. The brother and sister displayed VHL type 2B and type 2A features, respectively. Renal lesions in the brother exhibited 3 different phenotypes, including simple renal cysts, multilocular cystic renal cell carcinoma and clear cell renal cell carcinoma. The phenotypes of the 3 concurrent renal lesions were first reported in this study. Mutation detection of the VHL gene revealed 2 recurrent mutations, namely c.256C>T (p.P86S) and c.340 + 5G > C. The former was predicted to be deleterious and to destabilize the hydrophobic core and lead to VHL dysfunction; however, the latter was predicted to be a benign variant. Our findings provided new data for the genotype-phenotype of VHL diseases and elucidated the pathogenic mechanism with in silico analysis.
Collapse
Affiliation(s)
- Ping Yuan
- a Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Obstetrics and Gynecology, IVF Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China
| | - Qipeng Sun
- b Department of Urology , Lingnan Hospital, The Third Affiliated Hospital, Sun Yat-sen University , Guangzhou , China
| | - Hao Liang
- c Center for Quantitative Biology, Peking University , Beijing , China.,d BNLMS, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, and Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University , Beijing , China
| | - Wenjun Wang
- a Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Obstetrics and Gynecology, IVF Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China
| | - Ling Li
- a Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Obstetrics and Gynecology, IVF Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China
| | - Ye Wang
- e Department of Medical Genetics , Zhongshan School of Medicine and Center for Genome Research, Sun Yat-sen University , Guangzhou , China
| | - Huan Deng
- f Department of Pathology , The Third Affiliated Hospital, Sun Yat-sen University , Guangzhou , China
| | - Luhua Lai
- c Center for Quantitative Biology, Peking University , Beijing , China.,d BNLMS, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, and Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University , Beijing , China
| | - Xiaoli Chen
- a Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Obstetrics and Gynecology, IVF Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China
| | - Xiangfu Zhou
- b Department of Urology , Lingnan Hospital, The Third Affiliated Hospital, Sun Yat-sen University , Guangzhou , China
| |
Collapse
|
12
|
Binderup MLM, Budtz-Jørgensen E, Bisgaard ML. Risk of new tumors in von Hippel–Lindau patients depends on age and genotype. Genet Med 2015; 18:89-97. [DOI: 10.1038/gim.2015.44] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2014] [Accepted: 02/17/2015] [Indexed: 12/19/2022] Open
|
13
|
Hwang S, Ku CR, Lee JI, Hur KY, Lee MS, Lee CH, Koo KY, Lee JS, Rhee Y. Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel–Lindau (VHL) disease. J Hum Genet 2014; 59:488-93. [DOI: 10.1038/jhg.2014.61] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2014] [Revised: 06/19/2014] [Accepted: 06/26/2014] [Indexed: 01/09/2023]
|
14
|
INCREASEDCONTRACAECUM OSCULATUMINFECTION IN BALTIC COD (GADUS MORHUA) LIVERS (1982–2012) ASSOCIATED WITH INCREASING GREY SEAL (HALICHOERUS GRYPHUS) POPULATIONS. J Wildl Dis 2014; 50:537-43. [DOI: 10.7589/2012-12-320] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
15
|
Kumar PS, Venkatesh K, Srikanth L, Sarma PVGK, Reddy AR, Subramanian S, Phaneendra BV. Novel three missense mutations observed in Von Hippel-Lindau gene in a patient reported with renal cell carcinoma. INDIAN JOURNAL OF HUMAN GENETICS 2013; 19:373-6. [PMID: 24339559 PMCID: PMC3841571 DOI: 10.4103/0971-6866.120809] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary cancer syndrome that predisposes to the development of a variety of benign and malignant tumors, especially cerebellar hemangioblastomas, retinal angiomas and clear-cell renal cell carcinomas (RCC). We have identified of VHL gene using immunohistochemistry in a patient who was diagnosed for RCC. In order to understand the involvement of mutation in the VHL gene exon 1 was amplified and sequenced (accession number: JX 401534). The sequence analysis revealed the presence of novel missense mutations c.194 C>T, c.239 G>A, c.278 G>A, c.319 C>G, c. 337 C > G leading to the following variations p.Ala 65 Val, p.Gly 80 Asp, p.Gly 93 Glu, p.Gln 107 Glu, p.Gln 113 Glu in the protein.
Collapse
Affiliation(s)
- Pasupuleti Santhosh Kumar
- Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
| | | | | | | | | | | | | |
Collapse
|
16
|
|